AKI vs CKD: How to Tell Them Apart
Both AKI and CKD present as a rising or elevated creatinine with impaired kidney function and can produce electrolyte and volume derangements. The core axis that separates them is chronicity: AKI is a recent (days-to-weeks) decline in a previously normal kidney, whereas CKD reflects months-to-years of structural damage with the endocrine and hematologic footprints of long-standing disease. Prior creatinine values, kidney size on ultrasound, and the presence of anemia and mineral bone disease are the anchors that tell them apart.
How to tell them apart
| Feature | Acute Kidney Injury (AKI) | Chronic Kidney Disease (CKD) |
|---|---|---|
| Prior creatinine | Normal baseline creatinine with a recent rise | Previously elevated creatinine (chronically abnormal) |
| Kidney size on ultrasound | Typically normal size (~9–12 cm) | Classically small (<9 cm) and echogenic — but notably normal or enlarged in diabetic nephropathy, HIV-associated nephropathy, amyloidosis, polycystic kidney disease, and infiltrative/obstructive disease |
| Anemia | Absent, or present only from an acute cause such as bleeding or hemolysis | Present — normocytic, normochromic from erythropoietin deficiency |
| Bone disease | Absent | Present — renal osteodystrophy from CKD mineral bone disease |
| PTH | Normal | Elevated — secondary hyperparathyroidism |
| Onset/time course | Days to weeks | Months to years |
| Reversibility | Often reversible; prompts urgent workup for reversible causes | Generally irreversible; management aims to slow progression |
The reasoning
Start by anchoring on chronicity. The most powerful single piece of data is a prior creatinine: a jump from a normal baseline points to AKI, while a chronically elevated value points to CKD. When prior labs are unavailable, lean on the chronicity markers — normocytic anemia from EPO deficiency, elevated PTH, renal osteodystrophy, and small, echogenic kidneys collectively indicate long-standing disease and support CKD even without baseline values. Interpret kidney size with care, however: several CKD etiologies (diabetic nephropathy, HIV-associated nephropathy, amyloidosis, polycystic kidney disease, and obstructive/infiltrative disease) preserve or enlarge kidney size, so normal-sized kidneys do not exclude chronic disease. Conversely, normal PTH, no anemia (or an identifiable acute source), and a normal baseline favor AKI and should trigger an urgent search for reversible causes. Recognize the hybrid: a patient with baseline CKD markers whose creatinine is now higher than their known elevated baseline has acute-on-chronic injury requiring workup for the new insult.
Key tests
- Prior/baseline creatinine: normal previously in AKI (a new rise); already elevated and relatively stable in CKD — prior lab values are the single most useful discriminator.
- Renal ultrasound: normal-sized kidneys (~9–12 cm) favor AKI; small, echogenic kidneys (<9 cm) indicate chronic parenchymal damage — but remember that diabetic nephropathy, HIV-associated nephropathy, amyloidosis, and polycystic kidney disease can maintain normal or enlarged kidneys despite established CKD.
- CBC/hemoglobin: normal or acutely low from a specific cause in AKI; normocytic, normochromic anemia of EPO deficiency in CKD (typically at eGFR <30–45).
- PTH: normal in AKI; elevated (secondary hyperparathyroidism) in CKD — a useful chronicity marker. Phosphorus is less discriminating, since it is elevated in CKD from impaired excretion but can also be markedly elevated in AKI from rhabdomyolysis or tumor lysis.
What they share
- Elevated serum creatinine and reduced GFR
- Impaired electrolyte and acid-base homeostasis (hyperkalemia, metabolic acidosis)
- Can present with a modestly elevated creatinine that still reflects significant kidney dysfunction
- Both may exist together as acute-on-chronic kidney disease when a new injury is superimposed on baseline CKD
- Hyperphosphatemia can occur in both — chronically from impaired excretion in CKD, or acutely from massive phosphate release in AKI etiologies like rhabdomyolysis and tumor lysis syndrome
Pitfalls
- Treating small echogenic kidneys as a universal marker of CKD — diabetic nephropathy, HIV-associated nephropathy, amyloidosis, polycystic kidney disease, and infiltrative/obstructive disease commonly show normal or enlarged kidneys despite chronic damage.
- Relying on phosphorus to distinguish AKI from CKD — it is elevated in CKD but can also be strikingly high in AKI from rhabdomyolysis or tumor lysis syndrome, so PTH and anemia are more reliable chronicity markers.
- Interpreting a 'new' creatinine in isolation: a creatinine of 2.5 means acute injury if the prior was 1.0 but stable chronic disease if the prior was 2.3.
- Missing acute-on-chronic kidney injury — a creatinine rising above a known elevated baseline is not simply 'their CKD' and needs its own workup.
- Dismissing a modestly elevated creatinine as insignificant; even a small rise can reflect substantial loss of kidney function.
- Attributing anemia in a suspected renal patient to EPO deficiency without ruling out iron deficiency, B12/folate deficiency, or acute blood loss.
Practice this the way the exam tests it — on branching cases where your decisions shape the patient.